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license (http://creativeAlthough their detection is commonly followed by an introduction of treatment, little is known about
how medications frequently used to treat vascular risk affect amyloid deposition.
Methods: A cross-sectional study of 156 subjects who underwent positron emission tomography
with PiB. Using linear regression, we tested whether blood pressure, cholesterol, overweight/obese
status, angiotensin receptor blockers (ARBs), beta-blockers, diuretics, angiotensin converting
enzyme inhibitors, and statins predicted amyloid deposition.
Results: The use of ARBs (b 5 2.15, P 5 .044) and diuretics (b 5 2.20, P 5 .006) predicted less
amyloid accumulation; older age (b5 .29, P, .001) and statins (b5 .23, P5 .004) were related to
greater amyloid deposition. Overweight and/or obese women had more cortical amyloid than their
peers.
Discussion: Prospective studies should confirm effects of drugs and increased body weight on am-
yloid accumulation and establish whether they translate into measurable clinical outcomes. Women
may be more susceptible to harmful effects of obesity.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Amyloid; PET-PiB; Vascular risk factors; Antihypertensive medications; Statins angiotensin receptor blockers;Diuretics; Brain; Healthy elderly1. Introduction
Alzheimer’s disease (AD) and vascular conditions are
increasingly common with age. Vascular disease contributes
to AD neurodegeneration [1–3] and may even initiate it [4].
This notion is supported both by epidemiologic studiesW.T. have an imaging patent which belongs to NYU.
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commons.org/licenses/by-nc-nd/4.0/).showing that atherosclerosis risk factors like hypertension,
high cholesterol, and obesity are associated with higher inci-
dence of cognitive impairment and AD [5], and by neuropa-
thology studies showing that indices of atherosclerosis
correlate with AD markers [6].
Amyloid ß deposition in extracellular plaques [7] and
vessel walls [4] is a key feature of AD. In animal studies, hy-
poperfusion and ischemia-activated gamma-secretase [8],
increased BACE1 gene transcription and expression, and
augmented Aß accumulation [9]. These observations sug-
gest that the association between vascular disorders and
AD could be mediated by changes in amyloid metabolism.imer’s Association. This is an open access article under the CC BY-NC-ND
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yloid deposition, measured with Pittsburgh compound B
(PET-PiB), is related to high blood pressure [10–12] and
abnormal markers of lipid metabolism [13,14]. Interestingly,
studies reporting on body mass index (BMI) and PiB found
an inverse relationship, with low BMI related to greater PiB
uptake [12,15]. Both of these observations were based on
subjects in their seventies or older, and the results might
have reflected weight loss in preclinical stages of the disease.
The detection of vascular risk is commonly followed by
the introduction of appropriate treatment aimed at risk modi-
fication. The treatment itself may affect PET measures of
brain amyloid accumulation, but this is largely unknown.
In a group of cognitively healthy adults and elderly, we
examined cross-sectionally the relationships between the
most common vascular risk factors: blood pressure, choles-
terol, and body weight, as well as frequently used antihyper-
tensive medications and statins, and brain amyloid
deposition measured with PET-PiB.
As women are more likely to suffer from AD than men
[16], and sex differences in risk factors for conversion to
AD [17] and in the associations between lipid levels and de-
mentia [18] have been reported, we also conducted explor-
atory analyses to examine whether the relationships between
vascular risk factors and PiB deposition differed by gender.2. Methods
2.1. Subjects
We studied 156 cognitively healthy subjects
(mean 6 standard deviation, age 60.4 6 10.4 years; educa-
tion 16.66 2.0 years; 67% women). Eighty-eight percent of
the group was Caucasian, 9% African American, 2.5%
Asian, and 0.5% Hispanic. All subjects were recruited by
the Center for Brain Health at the NYU School of Medicine
for longitudinal PET studies of aging, cognitive decline, and
AD risk factors. They were volunteers responding to adver-
tisement, subjects interested in research participation or
family members of cognitively impaired patients. All signed
IRB-approved consent forms and underwent medical, psy-
chiatric, and neurological assessments, blood tests, ECG,
MRI, and PET-PiB scans. PET examinations were per-
formed between March 2009 and November 2013. Mild
cognitive impairment and dementia were ruled out during
a diagnostic interview. All subjects had 26 points on the
mini mental state examination. Subjects scoring .17 on
the 17-item Hamilton Depression Scale [19], subjects with
brain tumor, neocortical infarction, and axis I disorders
were excluded.
Laboratory tests (in a fasting state) included complete
blood count, metabolic and lipid panel, liver function tests,
and urinalysis. The clinical evaluation included an interview
using the Brief Cognitive Rating Scale and rating on the
Global Deterioration Scale (GDS) [20]. All subjects were
diagnosed as cognitively healthy: with (GDS5 2) or without(GDS 5 1) subjective memory complaints. From a larger
pool of potential subjects, we report here on subjects
35 years, with technically good PET scans. Diagram in
Fig. 1 describes an initial and final study sample.
2.1.1. Neuropsychological assessment
To fully characterize the cognitive status of our partici-
pants, we performed cognitive testing. It included the Uni-
form Data Set Neuropsychological Test Battery as chosen
by National Alzheimer’s Coordinating Center: Logical
memory story A from Wechsler Memory Scale, (I: immedi-
ate and II: delayed recall), digits forward and backward,
digit symbol substitution test (DSST), Trail Making Test
parts A and B (TMT-A,B), Boston Naming Test (BNT), an-
imal and vegetable categories [21]. Subjects also received
tests from the Guild Memory Scale assessing immediate
and delayed recall of orally presented paragraphs (initial:
PARI, and delayed: PARD); and verbal paired associates
(initial: PRDI and delayed: PRDD) [22]. Tests results of
all tests were converted to age-adjusted, education-adjusted,
and gender-adjusted standardized scores (z-scores) based on
a normative population [23,24]. We subsequently grouped
cognitive tests into memory (logic I and II, PARD, PARI,
PRDD, and PRDI), executive function (TMT-B), attention
(digits forward and backward), processing speed (DSST
and TMT-A), and language (BNT, animals, and vegetables
categories) domains. The score for each domain was an
average of z scores of all tests combined.
2.1.2. Ascertainment of vascular risk factors
The presence of hypertension (HTN) was determined
based on current antihypertensive treatment or blood pres-
sure (BP) 140/90 mm Hg [25]. BP was taken in a sitting
position, after 5 minutes of rest. Of 50 subjects classified
as hypertensive 40 were taking medication, 10 were unmed-
icated with high blood pressure during in office visit. BMI
was calculated as [weight (pounds)! 703]/height2 (inches).
All the subjects were classified as having a normal weight:
BMI 24.99 or being overweight or obese: BMI 25. Sub-
jects currently being treated with cholesterol-lowering medi-
cation (statins) or subjects with total cholesterol .200 were
considered to have hypercholesterolemia [26].
2.1.2.1. Medication
We separately coded the following groups: angiotensin
receptor blockers (ARBs) acting through blocking angio-
tensin receptor 1; angiotensin converting enzyme inhibitors
(ACEi), preventing conversion of angiotensin I to angio-
tensin II; beta-blockers blocking b-adrenergic receptors in
the heart and vascular smooth muscles; diuretics increasing
water excretion from the body; statins and antidepressants.
We did not analyze calcium channel blockers separately
because these were taken only by five subjects.
2.1.2.2. Apolipoprotein E (APOE) genotyping
Genotyping was performed using polymerase chain reac-
tion as previously described [27]. Study subjects were
Fig. 1. A diagram representing initial and final study sample.
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or two ε4 alleles and otherwise negative (APOE ε42). Geno-
type data were available for 147 of 156 subjects.2.2. Imaging
2.2.1. MRI acquisition
All magnetic resonance imaging was performed on the
same quality-controlled 1.5-T GE scanner (GE, Milwaukee,
WI, USA). All participants received coronal T1-weightedand axial FLAIR (fluid attenuation inversion recovery)
scans. T1-weighted (gradient echo) scan parameters were
repetition time [TR] 5 35 ms, time to echo [TE] 5 2 ms,
flip angle [FA] 5 60, number of excitations [NEX] 5 1,
slice thickness: 1.6 mm, field of view [FOV] 5 200 mm,
matrix 5 256! 192 ! 124, reconstructed as 256! 256.
FLAIR images were acquired with TR 9279 ms, TE
127 ms, TI 2300 ms, FA 90

, NEX 5 1, slice thickness:
3.3 mm, FOV 240 mm, matrix 5 256 ! 192, as 256 !
256 images.
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Scans were performed using either an LS Discovery scan-
ner (G.E. Medical Systems, Milwaukee, WI; full width at
half maximum (FWHM) 5 5.4 mm, FOV5 30 cm) or Bio-
Graph PET/CT scanner (Siemens, Knoxville, TN;
FWHM 5 6.0 mm, FOV 5 50 cm). Before scanning, a
venous line was inserted in the antecubital vein, and subjects
rested in a quiet and dim room. Scanning started 60 minutes
after isotope injection and lasted 30 minutes. In each case,
15 mCi (w550MBq) of N-methyl[11C]2-(4’-methylamino-
phenyl)-6-hydroxy-benzothiazole (PiB; radiochemical pu-
rity .98%) was administered. Before each PET
examination, a CT transmission scan was acquired for atten-
uation correction with the same FOV as PET. All images
were corrected for photon attenuation, scatter, and radioac-
tive decay. Each PET-PiB volume was visually screened to
assure adequate full brain coverage from the apex to the infe-
rior margin of the cerebellum.
2.2.3. PiB-PET image processing
Images were processed using Multimodal Image Data
Analysis System package [28] (MIDAS, version 1.11) and
with Statistical Parametric Mapping (SPM, version 8) [29].
The 60–90 minutes PiB data were used to generate summed
images. They were co-registered to the corresponding T1-
MRI using the normalized mutual information algorithm im-
plemented in SPM. Subsequently, the T1-MRI images were
spatially normalized to the SPM T1 brain template in MNI
(Montreal Neurologic Institute) space. The same normaliza-
tion parameters were then applied to the PiB-PET images to
resample them into MNI space. An automated cerebellar re-
gion of interest (ROI), known to be spared by fibrillary am-
yloid, was used to extract the cerebellar uptake of PiB [30].
Each PET voxel in 60–90 minutes image was then divided
by the cerebellar intensity value. The resulting ratio images
were uniformly smoothed with 10-mm Gaussian kernel.
Automated ROIs [30] were applied to extract the estimates
of PiB deposition. For the purposes of this study, we created
a composite of PiB deposition from cortical regions known
to be AD-vulnerable: inferior parietal lobe, lateral temporal
lobe, medial frontal gyrus, posterior cingulate cortex, and
prefrontal cortex.2.3. Statistics
Categorical variables were compared with c2 test (or
Fisher exact when appropriate). T tests were used to
compare group means for continuous variables. When
covariates were needed, general linear models were used.
Correlations were assessed with Pearson coefficient.
Nonparametric tests were used to confirm the results.
General characteristics are presented by gender. They
were compared using t (Mann–Whitney U when appro-
priate) or c2 tests.
Relationships between vascular risk factors (systolic
blood pressure (SBP) and diastolic blood pressure (DBP),cholesterol levels, overweight/obese status) or medication
group and PIB deposition were tested using stepwise
(backward) linear regression. Age and gender were added
to the model. For exploratory purposes, interactions be-
tween gender and vascular risk factors were also added.
The most parsimonious model was chosen, which was
defined as a model including only significant and necessary
(main effects when interaction was present) terms. The
linear model was checked for violations of the model as-
sumptions (correct distribution of the residuals, correct
specification of the variance structure and linear relation-
ship between the response and the linear predictor). The
standardized b coefficients are reported for significant in-
dependent variables from the linear regression model, after
adjusting for other variables which significantly contrib-
uted to the model. The variables were centered for the
calculation of the higher order terms, to avoid multicolli-
nearity with the main effects and to make the standardized
b values more comparable. As log transformation did not
render PiB distribution normal, we reexamined the final
models created with raw PiB data using rank-transformed
PiB data. In two cases with already diagnosed and treated
hypertension, SBP or DBP values were missing. They were
replaced by means derived from the treated hypertensive
group.
Finally, using ANCOVA, we compared PiB deposition
between subjects taking different antihypertensive medica-
tion, unmedicated hypertensive, and normotensive individ-
uals. The same way we compared PiB binding between
statin users, unmedicated subjects with hypercholesterole-
mia, and individuals with normal cholesterol levels.
Statistical significance was defined as a P value ,.05.
SPSS (version 21; SPSS, Inc., Chicago, IL) software was
used for all analyses.3. Results
3.1. General characteristics
Amyloid deposition was higher in men (P 5 .02), who
also had higher triglycerides (P 5 .002), lower total choles-
terol (P5 .001), and lower HDL (P, .001) levels. Men were
more likely to take statins (P 5 .02) and less likely to take
diuretics (P5 .04) than women. Prevalence of hypertension,
being overweight/obese, hypercholesterolemia, APOE ε4
status, the use of ARBs, ACEi or beta-blockers, LDL levels,
and systolic (SBP) and diastolic (DBP) blood pressure did
not differ between genders (Table 1). Table 1 also presents
scores in each cognitive domain. Although not used in statis-
tical analyses, they illustrate that our group was indeed
cognitively healthy.
3.2. Vascular risk factors, medications, and amyloid
deposition
With linear regression, the best fit (F7,1495 7.2, P, .001)
was achieved with a model including age, statins, ARBs,
Table 1
Study variables by gender
Variable Women (n 5 105) Men (n 5 51) P value
Age (years) 60.4 6 9.7 61.0 6 11.6 .72
Educationb 16.6 6 1.9 16.7 6 2.0 .69
Cortical PiB deposition (ratio to cerebellum)b 1.11 6 .18 1.15 6 .19 .02
Overweight/obese (n, %) 51, 48 32, 63 .10
Systolic blood pressure (mmHg)b 118.7 6 15.7 120.0 6 14.9 .55
Diastolic blood pressure (mmHg)b 72.4 6 11.0 70.9 6 9.4 .44
Hypertension (n, %) 32, 30 18, 35 .54
Total cholesterol mg/dL 208.1 6 32.6 188.0 6 34.7 .001
HDL cholesterol mg/dLb 70.9 6 17.0 51.9 6 16.6 ,.001
LDL cholesterol mg/dL 119.6 6 27.3 113.1 6 31.1 .18
Triglycerides mg/dLb 86.3 6 39.6 115.5 6 57.4 .001
Hypercholesterolemia (n, %) 68, 65 32, 63 .80
Angiotensin receptor blockers (n, %) 8, 8 5, 10 .64
Angiotensin converting enzymes inhibitors (n, %)a 6, 6 4, 8 .61
Beta-blockers (n, %) 8, 8 5, 10 .64
Diuretics (n, %)a 13, 12 1, 2 .04
Antidepressants (n, %)a 8, 8 0, 0 .05
Statins (n, %) 17, 16 17, 33 .02
APOE ε4 genotype (n, %)* 42, 43 17, 35 .22
Memoryy .14 6 .74 2.04 6 .77 .15
Executive functions 2.14 6 .98 2.14 6 .90 .96
Attentionz 2.05 6 .83 2.17 6 1.32 .52
Processing speedz .05 6 .92 .02 6 .79 .87
Language .02 6 .77 2.14 6 .63 .21
NOTE. Data presented asmean6 SD,P given for comparisonswith c2 test or Fisher exact test when appropriate (denoted by a), t test orMann–WhitneyU test
(denoted by b), depending on data distribution.
NOTE. All antidepressants belonged to the selective serotonin reuptake inhibitors class.
Significant results are shown in bold.
*Data available for 147 subjects (98 women and 49 men).
yData available for 155 subjects (104 women and 51 men).
zData available for 154 subjects (103 women and 51 men).
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(Table 2). Older age and treatment with statins were associated
withmore amyloid accumulation,whereas ARBs and diuretics
were related to less amyloid. Among women, having BMI
25 was associated with greater amyloid deposition (median
test, P, .05), whereas overweight and/or obese men tended to
have less amyloid (median test, P 5 .07; Fig. 2).Table 2
Linear regression model: predicting amyloid deposition with vascular risk
factors and medications in the entire group, n 5 156
Model term Standardized b P value VIF
Main effects*
Age .29 ,.001 1.11
Gender 2.03 .67 1.09
Overweight/obese status .06 .43 1.10
ARBs 2.15 .04 1.08
Diuretics 2.20 .006 1.07
Statins .23 .004 1.21
2-way interactions
Gender! overweight/obese .24 .001 1.06
Abbreviations: ARBs, angiotensin receptor blockers; VIF, variance infla-
tion factor.
Significant results are shown in bold.
*Values for standardized b shown are before the addition of higher order
terms.Amyloid deposition differed between hypertensive
subjects treated with ARBs, diuretics, hypertensive subjects
using other antihypertensive medications, untreated hyper-
tensive subjects, and normotensive individuals
(F6,148 5 3.2 P 5 .015, after accounting for age and statin
use). Only one subject was treated with both ARBs and di-
uretics and was excluded from this analysis. Post hoc tests
revealed the differences between diuretic users and the
normotensive group (P 5 .01), between diuretic users and
hypertensive subjects treated with other drugs (P5 .02), be-
tween ARBs users and the normotensive group (P 5 .02),
and between ARBs users and hypertensive subjects treated
with other drugs (P 5 .03; Fig. 3).
Amyloid deposition also differed between subjects
treated with statins, subjects with untreated hypercholester-
olemia, and subjects with normal cholesterol levels
(F5,150 5 4.1, P 5 .02, after accounting for age, the use of
ARBs, and diuretics). Post hoc tests showed that treated sub-
jects had higher cortical amyloid than untreated subjects
with hypercholesterolemia (P 5 .006) and individuals with
normal cholesterol levels (P 5 .02) (Fig. 4). Cortical PiB
did not differ between users of hydrophilic (n 5 8) vs. lipo-
philic (n 5 26) statins.
We reexamined the relationships between vascular
risk factors and amyloid in subjects who were not
Fig. 2. Distribution of cortical amyloid deposition by gender-overweight/obese groups. Cortical PiB values represent ratio to cerebellum. Circles represent
normal-weight women, solid circles represent overweight/obese women, squares represent normal-weight men, and solid squares represent overweight/obese
men. With median test differences between: overweight/obese women and normal weight women, P , .05; overweight/obese men and normal weight men,
P 5 .07.
Fig. 3. Cortical amyloid deposition in hypertensive subjects treated with diuretics, ARBs, hypertensive subjects treated with other antihypertensive drugs, un-
treated hypertensive subjects, and individuals without HTN. Values presented are estimatedmean6 standard error after accounting for age and the use of statins.
Cortical PiB values represent ratio to cerebellum. Post hoc tests (LSD: least square difference), difference between: diuretic users and hypertensive subjects
treated with other drugs, P 5 .02; diuretic users and the normotensive group, P 5 .01; ARBs users and hypertensive subjects treated with other drugs,
P 5 .03; ARBs users and the normotensive group, P 5 .02.
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Fig. 4. Cortical amyloid deposition in subjects with normal cholesterol levels, untreated subjects with high cholesterol (above 200 mg/dL), and subjects treated
with statins. Values presented are estimatedmean6 standard error after accounting for age and the use of ARBs and diuretics. Cortical PiB values represent ratio
to cerebellum. Post hoc tests, difference between: subjects with normal cholesterol level and subjects treated with statins, P5 .02; untreated subjects with high
cholesterol and subjects treated with statins, P 5 .006.
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the best fit (F6,89 5 5.1, P , .001) included age, as well as
gender! overweight/obese and gender! SBP interactions
(Table 3). Older age was associated with more amyloid
deposition in the entire group. As in the bigger sample, over-
weight women tended to have more amyloid (P 5 .10),
whereas overweight men tended to have less amyloid
(P5 .10) than their respective normal-weight peers. Finally,
among women, higher SBP was positively correlated with
PiB binding (rho 5 .30, P 5 .02).
4. Discussion
Our study yielded several important findings. First, be-
sides age, the use of ARBs, diuretics and statins was theTable 3
Linear regression model: predicting amyloid deposition with vascular risk
factors in non-medicated subjects n 5 96
Model term Standardized b P value VIF
Main effects*
Age .34 .002 1.21
Gender 2.25 .014 1.06
Overweight/obese status .07 .52 1.24
SBP 2.12 .26 1.37
2-way interactions
Gender! overweight/obese .23 .017 1.08
Gender! SBP .21 .033 1.11
Abbreviations: SBP, systolic blood pressure; VIF, variance inflation factor.
Significant results are shown in bold.
*Values for standardized b shown are before the addition of higher order
terms.strongest predictor of amyloid deposition. Second, having
a BMI 25 was associated with greater amyloid deposition
in women but not in men.
Former studies of association between BP and PiB either
did not take medications into account [12], adjusted for it
[10], or treated it as a homogenous variable (classifying sub-
jects as medicated vs. unmedicated [11]). Our data indicate
that effects of medication can differ depending on type.
Namely, ARBs or diuretics were related to lower amyloid
accumulation, whereas this effect was not observed for other
BP-loweringmedications. Blood pressure value did not seem
to influence these relationships. The finding that ARBs are
related to less amyloid pathology corroborates recent human
and animal studies. In a large, predominantly male popula-
tion, the use of ARBs was related to lower rates of incident
AD than the use of lisinopril or vascular comparator [31].
A post-mortem study of almost 900 individuals with and
without AD showed that those taking ARBs had less amyloid
deposition [32]. Animal experiments revealed that ARBs
decreased accumulation of amyloid and phosphorylated tau
and reduced inflammatory responses in spontaneously hyper-
tensive stroke resistant rats [33]. In contrast, some found that
losartan did not alleviate amyloid pathology in transgenic
APP mice despite a significant positive effect on cerebrovas-
cular dysfunction andmemory consolidation [34]. In theON-
TARGET trial, neither ramipril nor telmisartan had any
influence on cognitive outcomes [35]. Substantial differences
in models of aging and disease, in the case of animal studies,
and population characteristics and study design, in the case of
human data, likely contributed to these discrepancies. There
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in amyloid deposition may be related to reduced inflamma-
tion, because blocking angiotensin receptor 1 (AT1) de-
creases brain inflammatory responses [36]. Similarly,
blocking AT1 reduces reactive oxygen species generation
[37] and thus potentially decreases amyloid accumulation.
Finally, improved vascular compliance [37] and conse-
quently improved amyloid clearance could also play a role.
The use of diuretics was also related to lower amyloid
deposition. An earlier epidemiologic study indicated that
treatment with diuretics (especially the potassium sparing
type) was associated with a reduced rate of AD 3 years
later [38]. Others reported that subjects taking potassium
sparing diuretics had better verbal learning and memory
than individuals treated with other classes of antihyperten-
sive drugs or medication-free peers [39], and that diuretics
decreased the risk of AD by 50%, irrespective of mean
SBP (above or below 140) [40]. Although the reasons
why diuretics work are not well understood, one study indi-
cated that furosemide prevented amyloid b oligomerization
and dissociated pre-aggregated amyloid b42 oligomers
[41]. Interactions with renin-angiotensin-aldosterone sys-
tem were also proposed [38].
Epidemiologic studies showed that midlife use of statins
may reduce the risk of AD [42], but in our cross-sectional
observation, statin users had more cortical amyloid than non-
users. Neither hypercholesterolemia status nor lipophilic or
hydrophilic nature of the drug affected the amyloid accumu-
lation. Our results differ from a previous study by Reed et al.,
who did not find any effects of statins on PiB-PET [14] and
from an earlier report showing that statins were related to
less amyloid in postmortem examination [43]. Considerably
older age and more vascular comorbidities in subjects in
both of these studies at least partly explain these differences.
Cholesterol homeostasis is crucial for the central nervous sys-
tem [44]. Despite the beneficial influence of statins on cardio-
vascular morbidity and mortality, some have postulated that
long-term statin use may have negative effects on the brain.
Reduction in cholesterol is related to increased risk of hemor-
rhage and small vessels disease [45]. In addition, statin use in-
creases the risk of diabetes [46], which in turn can alter
amyloid metabolism and clearance. In postmortem examina-
tion, the prevalence of cerebral amyloid angiopathy was
greater in the poststatin era than the prestatin era [45]. Clinical
studies failed to find benefits of statins on cognitive decline in
AD patients [47,48], and some observed that statin
discontinuation improved cognition in AD [49]. Finally, in
line with our finding, a recent retrospective study of nearly
1million nondemented statin users and nonusers found a rela-
tionship between acute memory loss and the initiation of ther-
apy with statins or other lipid-lowering drugs [50]. Overall,
our results contribute to the ongoing debate about the effects
of statins on the brain.
We observed that in women, being overweight/obese was
related to an increased amyloid deposition. The opposite
trend was observed in men. Obesity has been consistentlylinked to increased levels of pro-inflammatory markers (cy-
tokines and c-reactive protein [51]). We suggest that chronic
systemic inflammation may facilitate amyloid deposition by
intensifying brain inflammatory responses. Although it is
unclear why positive high BMI–amyloid association was
observed only among women, some precedents exist for
such differences. There are sex differences in body fat distri-
bution, metabolic and hormonal regulation of fat deposition,
and adipocytes function [52]. They could affect putative
obesity–amyloid pathways. Among men, overweight/obese
subjects tended to have less amyloid deposition. While
former studies found an inverse association between BMI
and PiB binding [12,15], we believe our result should be
treated with caution as highly skewed amyloid distribution
in men could contribute to our findings.
There was a significant positive correlation between
higher SBP and amyloid deposition among nonmedicated
women. This observation supports a previous study where
a similar relationship was reported [10] and also highlights
the fact that medication may obscure or modify relationships
between AD markers and vascular risk factors.
There are several limitations of our report. Study partici-
pants were rather young (mean age around 60). Among older
individuals with more risk factors, the relationships could be
more robust. However, studying the younger age group is
especially important, as preventive therapies should be initi-
ated early in the process, before brain damage becomes irre-
versible. Second, our group was predominantly Caucasian
with low levels of vascular comorbidity, so generalizability
is uncertain. Although reexaminations of relationships be-
tween vascular risk and PiB in a medication-free subgroup
revealed a new amyloid-SBP association, medication-free
subjects were by definition healthier, so lower levels of pa-
thology might have prevented us from discovering more
meaningful relationships. One can argue that because statin
users are more often overweight, body mass might have been
the driver behind statin–amyloid relationship. However,
statin use was a significant predictor of PiB retention even
when the BMI status was entered in the regression model.
It is possible that clinical characteristics dictating pre-
scription of specific classes of medication, for which we
were not able to account, could themselves affect amyloid
deposition. Moreover, information about treatment duration
was not available and that could introduce a bias. Ideally, one
should consider both short and long effects of treatment,
which may differentially affect vascular risk factors and
core features of AD pathology. We used single measurement
of blood pressure in the office setting, whereas it has been
showed that multiple measurements or 24-hour blood pres-
sure monitoring better correlates with brain pathology
[53]. Finally, the reported associations are only cross-
sectional and causality cannot be determined.
There are several implications of our study: First, while
assessing relationships between vascular risk factors and
brain measures, modifying effects of treatment must be
taken into account. Women may be particularly sensitive
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must be taken into consideration when planning future inter-
ventions. Finally, our findings add to mounting evidence that
some classes of medication may impact AD pathology.
However, prospective studies should confirm this effect
and establish whether such modifications translate into
measurable clinical outcomes.
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1. Systematic review:We conducted a review of articles
focusing on the relationship between vascular risk
factors and cortical amyloid accumulation in normal
elderly. While the possibility that vascular conditions
may affect hallmarks of AD pathology and risk for
clinical presentation is widely acknowledged, there
are almost no studies investigating how commonly
prescribed antihypertensive and lipid-lowering
medications affect amyloid deposition measured
in vivo with PET-PiB.
2. We showed that the use of ARBs and diuretics was
related to less amyloid accumulation,while statin users
hadmore cortical amyloid.Drug treatmentwas a stron-
ger predictor of PiB binding than vascular risk factors.
3. Future directions: Prospective, longitudinal studies
should confirm observed cross-sectional relation-
ships between certain classes of drugs and amyloid
deposition. Moreover, we offer that while assessing
relationships between vascular risk factors and brain
measures, modifying effects of treatment must be
taken into account.References
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